 ATLANTA, April 1, 2021 PRNewswire -- Inhibikase Therapeutics, Inc. Nasdaq: IKT, a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinsons disease PD and related disorders inside and outside of the brain, today reported financial results for the fourth quarter and full year ended December 31, 2020 and highlighted recent developments. Key Business and Clinical Highlights Completed Initial Public Offering: In December 2020, Inhibikase successfully completed its initial public offering IPO of 1,800,000 shares of common stock at a public offering price of 10.00 per share. 